These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 33443455)

  • 1. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada.
    Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ
    Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
    Li A; Garcia DA; Lyman GH; Carrier M
    Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants.
    Uppuluri EM; Burke KR; Haaf CM; Shapiro NL
    J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
    Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
    JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
    Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
    PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation prescribing patterns in patients with cancer.
    Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
    J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
    Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
    JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review.
    Landry S; Ip S; Shiu J; Bungard TJ
    J Thromb Thrombolysis; 2022 Jan; 53(1):176-181. PubMed ID: 34146236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
    Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
    J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.
    Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S
    JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
    Ay C; Beyer-Westendorf J; Pabinger I
    Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism.
    Quan S; Smith J; Wu C; Koshman SL; Nguyen B; Bungard TJ
    Thromb Res; 2020 Mar; 187():56-62. PubMed ID: 31955061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?
    Khorana AA; Yannicelli D; McCrae KR; Milentijevic D; Crivera C; Nelson WW; Schein JR
    Thromb Res; 2016 Sep; 145():51-3. PubMed ID: 27485998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism.
    Schaefer JK; Li M; Wu Z; Basu T; Barnes GD; Carrier M; Griggs JJ; Sood SL
    J Thromb Thrombolysis; 2021 Jul; 52(1):214-223. PubMed ID: 33544284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs.
    Schaefer JK; Li M; Wu Z; Basu T; Dorsch MP; Barnes GD; Carrier M; Griggs JJ; Sood SL
    J Thromb Haemost; 2021 Jan; 19(1):212-220. PubMed ID: 33104289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
    Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
    J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat and prevent venous thrombotic complications in patients with lymphoma.
    Schmidt RA; Lee AYY
    Blood; 2022 Mar; 139(10):1489-1500. PubMed ID: 34479364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.